ArticleCancer medicine2026
Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPatients with relapsed/refractory (R/R) testicular germ cell tumor (GCT) progressing after salvage chemotherapy only have palliative therapeutic options. Real-world data on this population are needed.
methodsAdult men with testicular GCT receiving palliative chemotherapy in the United States were identified in the Komodo Research Database (01/2016-03/2023; index date = date of palliative chemotherapy initiation). Treatment patterns were analyzed for patients with continuous health plan enrollment from diagnosis to index date. Clinical outcomes (time to real-world progression [TTrwP] and real-world overall survival [rwOS]) were assessed among patients with prior salvage chemotherapy using the Kaplan-Meier method.
resultsIn the treatment pattern analysis (N = 51; median age 32 years), median (interquartile range) time from diagnosis to first-line treatment was 0.9 (0.5-2.1) months, and to palliative chemotherapy was 12.5 (9.0-16.8) months. Index palliative chemotherapy regimens included gemcitabine-oxaliplatin (37.3%), oral etoposide (15.7%), and gemcitabine-oxaliplatin-paclitaxel (15.7%). Prior to palliative chemotherapy, 33 patients (64.7%) received salvage chemotherapy. In the clinical outcome analysis (N = 80; median age: 33 years), 49 (61.3%) patients were exposed to high-dose chemotherapy (HDCT; ±conventional-dose chemotherapy [CDCT]) and 31 (38.8%) only to CDCT. Overall median (95% confidence interval [CI]) TTrwP was 3.8 (2.6-4.7) months, 3.5 (2.3-4.7) months after HDCT±CDCT, and 4.0 (1.7-6.6) months after only CDCT, and median (95% CI) rwOS was 7.7 (6.3-9.6) months, 6.4 (5.6-9.6) months, and 9.3 (7.5-22.0) months, respectively.
conclusionsReal-world data captured heterogeneous treatment patterns and poor outcomes for patients with R/R testicular GCT receiving palliative chemotherapy, highlighting the need for novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.